for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Kintor Pharmaceutical Ltd

9939.HK

Latest Trade

64.30HKD

Change

2.65(+4.30%)

Volume

5,781,108

Today's Range

55.05

 - 

65.15

52 Week Range

7.20

 - 

86.60

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
61.65
Open
61.45
Volume
5,781,108
3M AVG Volume
66.12
Today's High
65.15
Today's Low
55.05
52 Week High
86.60
52 Week Low
7.20
Shares Out (MIL)
387.59
Market Cap (MIL)
27,906.45
Forward P/E
-32.86
Dividend (Yield %)
--

Next Event

Full Year 2021 Kintor Pharmaceutical Ltd Earnings Release

Latest Developments

More

Kintor Pharma Says Unit Entered Proxalutamide Licensing Agreement

Kintor Pharmaceutical Received Investigational New Drug Clearance By Us FDA For GT20029 In US

Kintor Pharmaceutical Says A Shareholder To Sell 18.2 Mln Shares At A Price Of HK$64.50/Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Kintor Pharmaceutical Ltd

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.

Industry

Biotechnology & Drugs

Contact Info

No. 20 Songbei Road

Suzhou Industrial Park

SUZHOU, JNG

China

http://www.kintor.com.cn/

Executive Leadership

Tong Youzhi

Executive Chairman of the Board, Chief Executive Officer

Lu Yan

Chief Financial Officer

Yan Mingming

Vice President of Sales

Zhou Guohao

Chief Medical Officer (USA)

Dong Xunwei

Chief Medical Officer

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2020

0.0K

2021(E)

0.0K
EPS (CNY)

2020

-1.640

2021(E)

-1.579
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
14.71
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
14.70
LT Debt To Equity (MRQ)
8.98
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up